Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

FGFR3 (Fibroblast growth factor receptor 3)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Guardant360® CDx (54)

FoundationOne® Liquid CDx (21)

MSK-IMPACT (21)

Oncomine™ Dx Target Test (11)

FoundationOne® Heme CDx (10)

TruSeq®Amplicon - Cancer Panel (5)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

Oncomine™ Comprehensive Assay v3M (2)

therascreen® FGFR RGQ RT-PCR Kit (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

AVENIO Tumor Tissue Expanded Kit

AVENIO ctDNA Expanded Kit

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® FusionPlex® Myeloid Kit

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer™ FusionPlex™ Core Solid Tumor Panel

Archer™ VARIANTPlex™ Complete Solid Tumor panel

FusionPlex® Dx

FusionPlex® Pan Solid Tumor v2 panel

FusionPlex™ Pan-Heme panel

GALEAS™ Tumor

Ion AmpliSeq Colon and Lung Cancer Research Panel v2

Labcorp® Plasma Complete™

LiquidHALLMARK®

NeXT Dx™ Test

NeoLAB® Solid Tumor Liquid Biopsy

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

Oncomine Focus Assay

Oncomine Precision Assay

Oncomine Solid Tumor DNA Kit

Oncomine Tumor Mutation Load Assay

Oncotype MAP™ Pan-Cancer Tissue Test

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

Resolution ctDx Lung Assay™

SOPHiA DDM Dx RNAtarget Oncology Solution

SOPHiA DDM HRD Solution

SOPHiA DDM™ Solid Tumor Plus Solution

SafeSEQ HNSCC assay

StrataNGS™ Test

Tempus xF+ Panel

TruSight Oncology Comprehensive

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Fusion LBx Panel

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

Guardant360® CDx (54)

FoundationOne® Liquid CDx (21)

MSK-IMPACT (21)

Oncomine™ Dx Target Test (11)

FoundationOne® Heme CDx (10)

TruSeq®Amplicon - Cancer Panel (5)

Oncomine™ Pan-Cancer Cell-Free Assay (4)

TruSight Oncology 500 Assay (3)

Guardant360 TissueNext™ (2)

Oncomine™ Comprehensive Assay v3M (2)

therascreen® FGFR RGQ RT-PCR Kit (2)

Archer® FusionPlex® Comprehensive Thyroid & Lung (CTL) Kit (1)

AVENIO Tumor Tissue Expanded Kit

AVENIO ctDNA Expanded Kit

AmoyDx® HANDLE Classic NGS Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® FusionPlex® Myeloid Kit

Archer® VariantPlex® Comprehensive Thyroid and Lung (CTL) kit

Archer™ FusionPlex™ Core Solid Tumor Panel

Archer™ VARIANTPlex™ Complete Solid Tumor panel

FusionPlex® Dx

FusionPlex® Pan Solid Tumor v2 panel

FusionPlex™ Pan-Heme panel

GALEAS™ Tumor

Ion AmpliSeq Colon and Lung Cancer Research Panel v2

Labcorp® Plasma Complete™

LiquidHALLMARK®

NeXT Dx™ Test

NeoLAB® Solid Tumor Liquid Biopsy

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ CRC 2.0

NovoFocus™ NSCLC 2.0 Test

OncoGuide™ NCC Oncopanel System

OncoKey™ SL 525 Plus Assay

OncoKey™ SL 60 Plus Assay

Oncomine Focus Assay

Oncomine Precision Assay

Oncomine Solid Tumor DNA Kit

Oncomine Tumor Mutation Load Assay

Oncotype MAP™ Pan-Cancer Tissue Test

OptiSeq™ Lung Cancer Panel

OptiSeq™ Pan-Cancer Gene Panel

Resolution ctDx Lung Assay™

SOPHiA DDM Dx RNAtarget Oncology Solution

SOPHiA DDM HRD Solution

SOPHiA DDM™ Solid Tumor Plus Solution

SafeSEQ HNSCC assay

StrataNGS™ Test

Tempus xF+ Panel

TruSight Oncology Comprehensive

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Fusion LBx Panel

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

oncoReveal™ Solid Tumor v2 Panel

›

FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B
FGFR3 fusion	Urothelial Cancer	FGFR3 fusion	Urothelial Cancer	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B	erdafitinib Sensitive: B - Late Trials erdafitinib Sensitive : B
FGFR3 mutation	Cholangiocarcinoma	FGFR3 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Gastric Cancer	FGFR3 mutation	Gastric Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Solid Tumor	FGFR3 mutation	Solid Tumor	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Bladder Cancer	FGFR3 mutation	Bladder Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 overexpression	Urothelial Cancer	FGFR3 overexpression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR3 mutation	Bladder Cancer	FGFR3 mutation	Bladder Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Breast Cancer	FGFR3 mutation	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2